PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-51.43%
Negative net income growth while AGEN stands at 2.71%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
31.39%
D&A growth well above AGEN's 1.81%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
0.95%
SBC growth while AGEN is negative at -7.15%. John Neff would see competitor possibly controlling share issuance more tightly.
2999.17%
Well above AGEN's 18.94% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
284.36%
AP growth well above AGEN's 204.76%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
139.25%
Growth well above AGEN's 122.26%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
3478.66%
Well above AGEN's 214.77%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
582.93%
Operating cash flow growth above 1.5x AGEN's 17.06%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-3757.14%
Both yoy lines negative, with AGEN at -306.07%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3757.14%
We reduce yoy invests while AGEN stands at 46.13%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-4.55%
We cut debt repayment yoy while AGEN is 65.15%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.